National Planning Corporation’s BioCryst Pharmaceuticals BCRX Stock Holding History

National Planning Corporation’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-32,000	Closed	-$168K	–	91
2017 Q3	$168K	Sell	32,000 -4,000	-11%	-$20.5K	0.01%	643
2017 Q2	$210K	Sell	36,000 -2,700	-7%	-$16.4K	0.02%	661
2017 Q1	$321K	Sell	38,700 -150	-0.4%	-$1.04K	0.02%	500
2016 Q4	$228K	Sell	38,850 -2,000	-5%	-$10.4K	0.02%	580
2016 Q3	$183K	Sell	40,850 -150	-0.4%	-$599	0.01%	595
2016 Q2	$155K	Sell	41,000 -10,100	-20%	-$31.4K	0.01%	621
2016 Q1	$145K	Sell	51,100 -200	-0.4%	-$886	0.01%	601
2015 Q4	$315K	Sell	51,300 -3,000	-6%	-$29.8K	0.03%	503
2015 Q3	$538K	Sell	54,300 -9,700	-15%	-$129K	0.05%	329
2015 Q2	$732K	Sell	64,000 -150	-0.2%	-$1.71K	0.07%	275
2015 Q1	$594K	Sell	64,150 -5,900	-8%	-$61.1K	0.05%	305
2014 Q4	$846K	Buy	70,050 +2,000	+3%	+$22.1K	0.06%	282
2014 Q3	$871K	Buy	+68,050	New	+$834K	0.07%	270

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

National Planning Corporation's BCRX Position: Q4 2017 in Review

National Planning Corporation sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2017, closing a stake of 32,000 shares — an estimated $168K sold.

National Planning Corporation first reported a position in BCRX in Q3 2014 and held it in 13 quarters. The position peaked at $871K in Q3 2014. 116 funds tracked by Wall St. Rank hold BCRX as of Q4 2017.

National Planning Corporation reported no remaining BioCryst Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
National Planning Corporation sold 32,000 BioCryst Pharmaceuticals shares in Q4 2017, an estimated $168K.
National Planning Corporation first reported a position in BioCryst Pharmaceuticals in Q3 2014 and held it in 13 quarters.
National Planning Corporation's BioCryst Pharmaceuticals position peaked at $871K in Q3 2014.
116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2017.

Based on National Planning Corporation's 13F filing for Q4 2017, filed 14 Feb 2018.